Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Hejie Zhitong prescription
- Development stage
- Preclinical
01
Overview
Hejie Zhitong prescription (HJZT) is a traditional medicine formulation that has been utilized clinically for many years in the treatment of migraine. Research indicates that HJZT promotes sleep and inhibits nociceptive transmission-associated neurotransmitter activity, which are key mechanisms in its antimigraine effects. Its mechanism involves modulating neurotransmitters related to pain transmission and demonstrating a synergistic effect with pentobarbital sodium on promoting sleep.
02
Targets
Calcitonin gene-related peptide type 1 receptorCNR1 (Cannabinoid receptor 1)CCKAR (Cholecystokinin A receptor)PTGS2 (Prostaglandin-Endoperoxide Synthase 2)
Beyond the preview
Go deeper on Hejie Zhitong prescription.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Hejie Zhitong prescription.